Subscribe
shutterstock_1010946472_nitpicker-2
nitpicker / Shutterstock.com
1 July 2020Big Pharma

Chiesi blocks Japanese drugmaker’s new brand at EU General Court

Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker  Chiesi Farmaceutici.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing
8 March 2022   Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.
Europe
Teva to face inhaler infringement allegations in UK court
3 June 2020   Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
Generics
EC plans to lower barriers to generic drugs
25 November 2020   The European Commission wants to increase access to generic medicines and crack down on anti-competitive behaviour in the pharmaceutical industry, a new plan has said.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Biotechnology
Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing
8 March 2022   Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.
Europe
Teva to face inhaler infringement allegations in UK court
3 June 2020   Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
Generics
EC plans to lower barriers to generic drugs
25 November 2020   The European Commission wants to increase access to generic medicines and crack down on anti-competitive behaviour in the pharmaceutical industry, a new plan has said.

More on this story

Biotechnology
Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing
8 March 2022   Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.
Europe
Teva to face inhaler infringement allegations in UK court
3 June 2020   Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
Generics
EC plans to lower barriers to generic drugs
25 November 2020   The European Commission wants to increase access to generic medicines and crack down on anti-competitive behaviour in the pharmaceutical industry, a new plan has said.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court